SCHEMBL3728403

SCHEMBL3728403

CN(Cc1nnc(NC(=O)c2ccc3c(c2)CCN(C(=O)OC(C)(C)C)C3)s1)c1ccccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.48
MAPK1 P28482 2/20 0.48
GLA P06280 1/20 0.48
NOD2 Q9HC29 1/20 0.48
ESR2 Q92731 1/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
HPGD P15428 2/20 0.45
ALDH1A1 P00352 1/20 0.45
POLB P06746 1/20 0.45
GRAMD1A Q96CP6 1/20 0.40
GLS O94925 1/20 0.40
KDM4E B2RXH2 1/20 0.40
HTT P42858 1/20 0.40
HSD17B10 Q99714 1/20 0.40
GCK P35557 4/20 0.39
NR1H2 P55055 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3734829 0.86 LMNA (0.51) LMNAMAPK1GLANOD2ESR2
SCHEMBL3727652 0.85 LMNA (0.50) LMNAMAPK1GLANOD2ESR2
SCHEMBL3729473 0.85 ESR2 (0.51) LMNAMAPK1GLANOD2ESR2
SCHEMBL3727140 0.85 LMNA (0.49) LMNAMAPK1GLANOD2ESR2
SCHEMBL3732043 0.84 LMNA (0.48) LMNAMAPK1GLANOD2ESR2
SCHEMBL3733053 0.84 LMNA (0.48) LMNAMAPK1GLANOD2ESR2
SCHEMBL3740010 0.83 RXFP1 (0.53) LMNAMAPK1GLANOD2ESR2
SCHEMBL3723583 0.82 ESR2 (0.49) LMNAMAPK1GLANOD2ESR2
SCHEMBL3730980 0.82 NPC1 (0.53) LMNAMAPK1GLANOD2ESR2
SCHEMBL3732036 0.82 LMNA (0.49) LMNAMAPK1GLANOD2ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100120669-A1 THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE BOUILLOT ANNE MARIE JEANNE 2010-05-13 US disclosed
US-20100120669-A1 THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE BOUILLOT ANNE MARIE JEANNE 2010-05-13 US disclosed
US-20100120669-A1 THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE BOUILLOT ANNE MARIE JEANNE 2010-05-13 US disclosed
WO-2008104524-A1 THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE SMITHKLINE BEECHAM CORPORATION (US) 2008-09-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120669-A1 THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE SCD, SCD5, FADS2 LMNA 2761/4885MAPK1 3108/4885GLA 1875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.